YAFO Acts as Financial Advisor for Starton Therapeutics in its Licensing-out Transaction with Haisco Pharma
Starton Therapeutics entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ in Mainland China with Haisco Pharmaceuticals co,. LTD.
雅法协助Starton Therapeutics和海思科制药完成商业许可交易合作
Transaction Overview 交易概览
• Starton Therapeutics entered into an exclusive licensing agreement for the development and commercialization of STAR-OLZ in Mainland China with Haisco Pharmaceuticals co,. LTD.
Starton Therapeutics与 Haisco Pharmaceuticals Co., LTD（海思科制药）在中国大陆地区签署奥氮平透皮贴剂合作协议。
• Starton will be eligible to receive an undisclosed upfront cash payments pand is eligible to receive additional development and regulatory mileston payments, plus double-digit royalties on annual net sales of STAR-OLZ in the territory.
Starton Therapeutics 将获得750万美元的现金预付款及潜在开发和注册里程碑付款，以及STAR-OLZ在该地区的年度净销售额的两位数特许权使用费。
• Shanghai YAFO Capital (YAFO Life Science) acted as the financial advisor on this transaction for Starton Therapeutics
上海雅法资本（雅法全球医疗）担任 Starton Therapeutics财务顾问。
About Starton Therapeutics
Starton Therapeutics is a clinical stage biotechnology company located in the United States. The company combines mature transdermal technology with its self-developed formula to obtain new indications. The company‘s technology comes from a well-known university professor in the United States, the professor has decades of research experience in the field of transdermal drug delivery technology, published more than 100 papers, and published three books. The company received investment from a well-known family fund of Stanford University.
Starton Therapeutics是一家位于美国的临床阶段的生物技术公司。该公司将成熟的透皮技术与其自主研发的配方相结合，以获得新的适应症。该公司的技术来自于美国某知名大学教授，该教授在透皮给药技术领域有数十年的研究经验，发表超过 100 篇论文，并出版了三部著作。该公司获得了 Stanford 大学某知名家族基金的投资。
About Haisco 海思科制药
Haisco Pharmaceutical Group Co., Ltd. Established in 2000, and it is a diversified and specialized pharmaceutical group listed company integrating new drug research and development, manufacturing, and sales. The company's R&D strength ranks among the best in the chemical and pharmaceutical industry, and has the largest market share in the parenteral nutrition segment. It is the fifth largest manufacturer of liver disease drugs in the country and occupies an important position in the liver disease and digestion and anti-infection segments.
海思科医药集团股份有限公司成立于2000年，是一家集新药研发、生产制造、销售等业务于一体的多元化、专业化医药集团上市公司。公司的研发实力在化学制药行业中名列前茅，在肠外营养细分市场占有率第一，是全国第五大肝病用药生产企业，在肝病及消化和抗感染两个细分市场占据重要地位。
About YAFO Life Science 雅法全球医疗
YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com
雅法全球医疗（YAFO Life Science）是雅法资本旗下的医疗大健康部门，专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作；为中国医疗企业提供产品全球授权、海外市场研究服务，寻找海外投资并购标的，及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验；雅法庞大的海外的区域合伙人团队，均具20+年医药行业及交易经验，覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系：黎琦 | BD Director | 13621979227 | qli@yafocapital.com
Recent Transaction
YAFO Upcoming Events - ACCESS CHINA Forum 2021 -Summer Showcase (June 9-11, 14-18, 2021, Bio Convention Week)
雅法药通中国夏季路演活动将于2021年6月Bio Convention Week期间举行。
Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.
